Akebia Therapeutics, Inc. (AKBA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Akebia Therapeutics reported revenue of $236.2M, up 47.5% from $160.2M the year before. Net income was -$5.3M (a -2.3% net margin), or -$0.02 per diluted share. Gross margin was 83.3% and operating margin was 9.9%. Operating activities generated $68.0M of cash, leaving $67.7M of free cash flow. At fiscal year end, Akebia Therapeutics held $376.6M in total assets against $344.0M in total liabilities, including $184.8M of cash and equivalents.
Open the full interactive Akebia Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Akebia Therapeutics Key Stats
| Share Price | $0.77 |
|---|---|
| Market Cap | $207.6M |
| Revenue YoY Growth | +47.5% |
| 52-Week Range | $0.77 – $3.17 |
| Shares Outstanding | 269.6 million (basic, 2026 Q2) |
Akebia Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $295.3M | $213.6M | $292.6M | $194.6M | $160.2M | $236.2M |
| Gross Profit | -$601,000 | $60.2M | $207.8M | $120.5M | $97.0M | $196.7M |
| Operating Income | -$376.4M | -$265.3M | -$79.1M | -$46.3M | -$50.5M | $23.5M |
| Pre-Tax Income | -$383.5M | -$282.8M | -$92.6M | -$51.9M | -$69.4M | -$3.7M |
| Income Tax | $0 | $0 | $0 | — | — | $1.6M |
| Net Income | -$383.5M | -$282.8M | -$92.6M | -$51.9M | -$69.4M | -$5.3M |
| Diluted EPS | -$2.77 | -$1.70 | -$0.51 | -$0.28 | -$0.33 | -$0.02 |
Akebia Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $58.8M | $57.6M | $53.5M | $49.1M |
| Net Income | $540,000 | -$12.2M | -$9.1M | -$8.9M |
| Diluted EPS | — | -$0.05 | -$0.03 | -$0.03 |
Akebia Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $228.7M | $149.8M | $90.5M | $42.9M | $51.9M | $184.8M |
| Current Assets | $371.4M | $272.0M | $184.9M | $118.1M | $113.8M | $253.0M |
| Total Assets | $644.1M | $525.5M | $351.8M | $241.7M | $220.7M | $376.6M |
| Current Liabilities | $187.1M | $256.5M | $124.8M | $99.9M | $80.9M | $162.9M |
| Total Long-Term Debt | $96.4M | $195.1M | $66.1M | $34.7M | $38.7M | $48.2M |
| Total Liabilities | $396.5M | $449.1M | $342.5M | $272.3M | $269.9M | $344.0M |
| Shareholders' Equity | $247.6M | $76.5M | $9.3M | -$30.6M | -$49.2M | $32.6M |
Akebia Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$110.4M | -$253.0M | -$73.2M | -$23.4M | -$40.7M | $68.0M |
| Cash From Investing | -$40.0M | $39.9M | -$114,000 | $0 | -$33,000 | -$7.9M |
| Cash From Financing | $231.7M | $133.7M | $14.6M | -$25.2M | $49.7M | $72.9M |
| Free Cash Flow | -$110.7M | -$253.0M | -$73.3M | -$23.4M | -$40.7M | $67.7M |
Figures from Akebia Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Akebia Therapeutics financials page for every line item.
Akebia Therapeutics Company Profile
| Ticker | AKBA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001517022 |
Frequently Asked Questions
What was Akebia Therapeutics' revenue in fiscal 2025?
Akebia Therapeutics (AKBA) reported revenue of $236.2M for fiscal 2025.
What is Akebia Therapeutics' annual revenue history?
Akebia Therapeutics' annual revenue by fiscal year: 2020: $295.3M; 2021: $213.6M; 2022: $292.6M; 2023: $194.6M; 2024: $160.2M; 2025: $236.2M.
What was Akebia Therapeutics' net income in fiscal 2025?
Akebia Therapeutics reported net income of -$5.3M for fiscal 2025.
What was Akebia Therapeutics' earnings per share (EPS) in fiscal 2025?
Akebia Therapeutics' diluted EPS was -$0.02 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Akebia Therapeutics generate in fiscal 2025?
Akebia Therapeutics generated $67.7M of free cash flow in fiscal 2025.
What was Akebia Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Akebia Therapeutics reported revenue of $49.1M.
How much debt does Akebia Therapeutics have?
Akebia Therapeutics reported $48.2M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Akebia Therapeutics are outstanding?
Akebia Therapeutics reported a weighted average of 269.6 million basic shares outstanding in 2026 Q2.
What is Akebia Therapeutics' market cap?
Based on its latest closing price, Akebia Therapeutics (AKBA) has a market capitalization of about $207.6M.
When does Akebia Therapeutics' fiscal year end?
Akebia Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Akebia Therapeutics headquartered?
Akebia Therapeutics lists its business address in Cambridge, Massachusetts in its SEC filings.